NASDAQ:CLVS - Clovis Oncology Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.88
  • Forecasted Upside: 181.76 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.44
+0.30 (1.20%)

This chart shows the closing price for CLVS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Clovis Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLVS

Analyst Price Target is $6.88
▲ +181.76% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Clovis Oncology in the last 3 months. The average price target is $6.88, with a high forecast of $9.00 and a low forecast of $4.75. The average price target represents a 181.76% upside from the last price of $2.44.

This chart shows the closing price for CLVS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Clovis Oncology. This rating has held steady since October 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 2 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 2 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/3/2021Piper SandlerLower Price TargetNeutral$5.50 ➝ $4.75High
9/21/2021HC WainwrightLower Price TargetBuy$10.00 ➝ $9.00Medium
8/5/2021HC WainwrightLower Price TargetBuy$12.00 ➝ $10.00High
5/5/2021HC WainwrightLower Price TargetBuy$13.00 ➝ $12.00High
2/23/2021HC WainwrightLower Price TargetBuy$15.00 ➝ $13.00Low
1/14/2021HC WainwrightReiterated RatingBuy$15.00High
1/8/2021HC WainwrightReiterated RatingBuyMedium
11/6/2020HC WainwrightLower Price TargetBuy$23.00 ➝ $15.00High
11/5/2020Piper SandlerLower Price TargetNeutral$6.00 ➝ $5.00Medium
11/1/2020JPMorgan Chase & Co.Reiterated RatingHoldMedium
9/21/2020HC WainwrightReiterated RatingBuy$23.00Medium
9/3/2020HC WainwrightReiterated RatingBuyLow
8/6/2020HC WainwrightReiterated RatingBuyLow
5/20/2020SVB LeerinkLower Price TargetUnderperform$5.00 ➝ $4.00Medium
5/18/2020HC WainwrightBoost Price TargetBuy$29.00 ➝ $33.00High
5/6/2020HC WainwrightBoost Price TargetBuy$27.00 ➝ $29.00High
5/6/2020Piper SandlerBoost Price TargetNeutral$5.25 ➝ $6.00High
4/27/2020SVB LeerinkDowngradeMarket Perform ➝ Underperform$5.00Medium
4/20/2020Royal Bank of CanadaReiterated RatingBuy$17.00Medium
4/19/2020Bank of AmericaDowngradeNeutral ➝ UnderperformHigh
4/15/2020HC WainwrightReiterated RatingBuy$27.00Medium
4/9/2020Bank of AmericaDowngradeNeutral ➝ Underperform$6.00Low
2/25/2020Royal Bank of CanadaInitiated CoverageOutperformHigh
1/16/2020HC WainwrightReiterated RatingBuyLow
1/14/2020JPMorgan Chase & Co.Reiterated RatingHoldLow
1/8/2020HC WainwrightReiterated RatingBuy$36.00 ➝ $27.00High
11/27/2019Evercore ISIDowngradeOutperform ➝ In-LineHigh
10/31/2019Piper Jaffray CompaniesLower Price TargetNeutral$11.00 ➝ $4.00High
9/30/2019HC WainwrightSet Price TargetBuy$36.00Medium
9/30/2019JPMorgan Chase & Co.Reiterated RatingHoldMedium
9/27/2019Bank of AmericaSet Price TargetHold$7.00Medium
9/24/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$22.00 ➝ $10.00High
9/23/2019HC WainwrightSet Price TargetBuy$36.00Low
8/13/2019Bank of AmericaDowngradeBuy ➝ Neutral$13.00 ➝ $7.00Medium
8/2/2019G.ResearchReiterated RatingBuyHigh
8/2/2019BarclaysSet Price TargetBuy$36.00Low
8/2/2019Royal Bank of CanadaSet Price TargetBuy$26.00Low
8/2/2019GabelliReiterated RatingBuyHigh
8/1/2019GuggenheimDowngradeBuy ➝ NeutralHigh
8/1/2019Piper Jaffray CompaniesReiterated RatingNeutralMedium
7/3/2019HC WainwrightReiterated RatingBuyLow
6/3/2019JPMorgan Chase & Co.Reiterated RatingHold$27.00Low
5/29/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$17.00 ➝ $15.00Low
5/21/2019HC WainwrightReiterated RatingBuy$36.00Low
5/15/2019Credit Suisse GroupReiterated RatingBuy$29.00High
4/15/2019SunTrust BanksLower Price TargetBuy$28.00Medium
4/15/2019HC WainwrightLower Price TargetBuy ➝ Buy$39.00 ➝ $37.00Low
4/14/2019Piper Jaffray CompaniesLower Price TargetNeutral$23.00 ➝ $21.00Medium
4/7/2019JPMorgan Chase & Co.Reiterated RatingHoldMedium
2/27/2019SunTrust BanksBoost Price TargetBuy$35.00High
2/27/2019JPMorgan Chase & Co.Reiterated RatingHold$27.00High
2/27/2019Piper Jaffray CompaniesBoost Price TargetNeutral$23.00High
2/13/2019HC WainwrightInitiated CoverageBuy ➝ Buy$40.00Medium
12/11/2018GabelliReiterated RatingBuyLow
12/4/2018SVB LeerinkUpgradeMarket Perform ➝ OutperformHigh
10/31/2018BarclaysLower Price TargetOverweight ➝ Overweight$58.00 ➝ $40.00High
10/31/2018Piper Jaffray CompaniesLower Price TargetNeutral$18.00High
10/31/2018SunTrust BanksDowngradeBuy$20.00 ➝ $70.00High
10/31/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$71.00 ➝ $16.00High
10/30/2018OppenheimerReiterated RatingHoldHigh
10/21/2018JPMorgan Chase & Co.Reiterated RatingBuyHigh
10/19/2018Piper Jaffray CompaniesReiterated RatingNeutral ➝ NeutralLow
10/18/2018Piper Jaffray CompaniesInitiated CoverageHold$33.00High
10/2/2018JPMorgan Chase & Co.Reiterated RatingBuyHigh
9/24/2018SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$30.00High
9/21/2018JPMorgan Chase & Co.Reiterated RatingBuy$71.00Medium
9/17/2018GuggenheimInitiated CoverageBuyLow
7/16/2018GabelliReiterated RatingBuyMedium
6/12/2018Royal Bank of CanadaReiterated RatingBuy$73.00High
4/26/2018Credit Suisse GroupSet Price TargetBuy$86.00Low
4/9/2018Bank of AmericaLower Price TargetBuy$90.00 ➝ $55.52High
4/9/2018SunTrust BanksBoost Price TargetBuy$90.00High
4/6/2018Credit Suisse GroupSet Price TargetBuy$86.00High
2/27/2018SunTrust BanksLower Price TargetPositive ➝ Buy$95.00 ➝ $85.00Medium
2/27/2018Stifel NicolausLower Price TargetBuy ➝ Buy$125.00 ➝ $110.00Medium
2/27/2018BarclaysSet Price TargetOverweight ➝ Buy$105.00 ➝ $85.00High
2/22/2018Evercore ISIUpgradeIn-Line ➝ Outperform$72.00High
2/22/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$81.00High
1/18/2018Credit Suisse GroupSet Price TargetBuy$107.00 ➝ $86.00Medium
1/11/2018JPMorgan Chase & Co.Reiterated RatingBuyHigh
12/20/2017OppenheimerReiterated RatingHoldHigh
11/15/2017SVB LeerinkReiterated RatingOutperform$107.00 ➝ $90.00N/A
11/3/2017Stifel NicolausReiterated RatingBuy$125.00N/A
11/2/2017Morgan StanleyLower Price TargetOverweight$89.00 ➝ $86.00N/A
10/23/2017BarclaysInitiated CoverageOverweight ➝ Overweight$105.00N/A
10/10/2017OppenheimerReiterated RatingHoldN/A
9/18/2017SVB LeerinkReiterated RatingBuy$107.00Low
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform$81.00Low
9/11/2017OppenheimerReiterated RatingHoldLow
8/18/2017JPMorgan Chase & Co.Reiterated RatingBuyMedium
8/18/2017SVB LeerinkLower Price TargetOutperform$107.00High
8/16/2017Evercore ISIInitiated CoverageIn ➝ In-Line$73.00High
8/10/2017Morgan StanleyReiterated RatingOverweight$93.00Medium
8/3/2017Bank of AmericaReiterated RatingBuyLow
8/1/2017JPMorgan Chase & Co.Reiterated RatingOverweightHigh
7/18/2017Credit Suisse GroupSet Price TargetBuy$107.00Low
7/7/2017GabelliInitiated CoverageBuy$125.00High
6/23/2017OppenheimerInitiated CoverageMarket PerformLow
6/22/2017SunTrust BanksReiterated RatingBuyLow
6/20/2017JPMorgan Chase & Co.Reiterated RatingOverweight$72.00 ➝ $111.00High
6/20/2017The Goldman Sachs GroupReiterated RatingNeutral$67.00 ➝ $90.00High
6/20/2017Janney Montgomery ScottUpgradeNeutral ➝ BuyMedium
6/20/2017Bank of AmericaLower Price TargetBuy$103.00 ➝ $75.00High
6/20/2017Morgan StanleyReiterated RatingOverweight$79.00High
6/19/2017SVB LeerinkBoost Price TargetOutperform$85.00 ➝ $114.00High
6/19/2017Stifel NicolausBoost Price TargetBuy$86.00 ➝ $125.00High
6/19/2017Chardan CapitalUpgradeSell ➝ Neutral$36.00 ➝ $50.00High
6/16/2017Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$88.00Medium
6/13/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$85.00High
6/1/2017JPMorgan Chase & Co.Set Price TargetBuy$72.00Medium
5/17/2017Bank of AmericaReiterated RatingBuy$75.00Medium
5/17/2017JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$72.00High
5/2/2017Morgan StanleyReiterated RatingOverweight$79.00High
4/18/2017Credit Suisse GroupReiterated RatingOutperform$74.00Low
3/28/2017Piper Jaffray CompaniesSet Price TargetBuy$77.00Low
3/16/2017Chardan CapitalReiterated RatingSell$36.00Low
3/15/2017The Goldman Sachs GroupBoost Price TargetNeutral$44.00 ➝ $75.00High
3/15/2017JPMorgan Chase & Co.Reiterated RatingHoldHigh
3/14/2017Piper Jaffray CompaniesSet Price TargetBuy$77.00High
2/23/2017JPMorgan Chase & Co.Set Price TargetHold$58.00N/A
2/23/2017Morgan StanleyBoost Price TargetOverweight$68.00 ➝ $72.00N/A
2/23/2017Credit Suisse GroupBoost Price TargetOutperform$53.00 ➝ $70.00N/A
2/3/2017Chardan CapitalDowngradeNeutral ➝ Sell$36.00N/A
1/27/2017Bank of AmericaInitiated CoverageBuy$74.00N/A
1/26/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$77.00N/A
1/23/2017Stifel NicolausBoost Price TargetBuy$52.00 ➝ $86.00N/A
(Data available from 1/19/2017 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2021
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/22/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/21/2021
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/21/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/20/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/19/2022

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Clovis Oncology logo
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Read More

Today's Range

Now: $2.44
Low: $2.44
High: $2.60

50 Day Range

MA: $3.02
Low: $2.44
High: $3.99

52 Week Range

Now: $2.44
Low: $2.43
High: $11.10

Volume

4,280,958 shs

Average Volume

4,174,908 shs

Market Capitalization

$317.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Clovis Oncology?

The following sell-side analysts have issued stock ratings on Clovis Oncology in the last year: HC Wainwright, and Piper Sandler.
View the latest analyst ratings for CLVS.

What is the current price target for Clovis Oncology?

2 Wall Street analysts have set twelve-month price targets for Clovis Oncology in the last year. Their average twelve-month price target is $6.88, suggesting a possible upside of 181.8%. HC Wainwright has the highest price target set, predicting CLVS will reach $9.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $4.75 for Clovis Oncology in the next year.
View the latest price targets for CLVS.

What is the current consensus analyst rating for Clovis Oncology?

Clovis Oncology currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLVS will outperform the market and that investors should add to their positions of Clovis Oncology.
View the latest ratings for CLVS.

How do I contact Clovis Oncology's investor relations team?

Clovis Oncology's physical mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company's listed phone number is 303-625-5000 and its investor relations email address is [email protected] The official website for Clovis Oncology is www.clovisoncology.com.